Sanofi/€SAN
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Ticker
€SAN
Sector
Primary listing
PAR
Industry
Pharmaceuticals
Headquarters
Employees
82,878
ISIN
FR0000120578
Website
Sanofi Metrics
BasicAdvanced
€100B
16.35
€5.04
0.48
€3.92
4.75%
Price and volume
Market cap
€100B
Beta
0.48
52-week high
€110.88
52-week low
€82.10
Average daily volume
2.1M
Dividend rate
€3.92
Financial strength
Total debt to equity
23.008
Interest coverage (TTM)
17.14%
Profitability
EBITDA (TTM)
12,148
Gross margin (TTM)
70.96%
Net profit margin (TTM)
13.95%
Operating margin (TTM)
20.80%
Effective tax rate (TTM)
20.10%
Revenue per employee (TTM)
€540,000
Management effectiveness
Valuation
Price to earnings (TTM)
16.351
Price to revenue (TTM)
2.278
Price to book
1.33
Price to tangible book (TTM)
5.19
Dividend yield (TTM)
4.75%
Forward dividend yield
4.75%
Growth
Revenue change (TTM)
-2.42%
Earnings per share change (TTM)
39.56%
3-year revenue growth (CAGR)
3.84%
10-year revenue growth (CAGR)
2.56%
3-year earnings per share growth (CAGR)
-1.65%
10-year earnings per share growth (CAGR)
4.46%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Bulls say / Bears say
Sanofi's acquisition of Blueprint Medicines for up to $9.5 billion is expected to diversify its portfolio and reduce dependence on Dupixent, with Blueprint's Ayvakit projected to generate over $2 billion by 2030. (ft.com)
Sanofi reported a 15.7% sales growth in Q3 2024, driven by strong performances from Dupixent and vaccines, leading to an upgraded 2024 business EPS guidance. (sanofi.com)
The company's strategic plan to invest at least $20 billion in the U.S. by 2030 aims to expand manufacturing capacity and R&D efforts, potentially enhancing its market presence and revenue streams. (reuters.com)
Sanofi's heavy reliance on Dupixent, which accounted for nearly a third of its 2024 revenue, poses a risk as the drug is set to lose exclusivity in the early 2030s. (ft.com)
The $9.5 billion acquisition of Blueprint Medicines, while strategic, involves integrating a company currently operating at a loss and facing competition, which could strain Sanofi's financials. (reuters.com)
Sanofi's recent R&D setbacks, including a failed COPD drug trial, raise concerns about the company's ability to develop successful new therapies. (ft.com)
Data summarised monthly by Lightyear AI. Last updated on 22 Jun 2025.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Sanofi News
AllArticlesVideos
Sanofi: Investing in prevention builds Europe's health and competitiveness
GlobeNewsWire·2 months ago
Press Release: Annual General Meeting of April 30, 2025
GlobeNewsWire·2 months ago
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SAN) has a market cap of €100B as of June 27, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SAN) stock is 16.35 as of June 27, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SAN) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is €3.92 and the yield is 4.75%. Sanofi has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SAN) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SAN) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.